Janux Therapeutics (JANX) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Janux Therapeutics (NASDAQ:JANX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.

Which has more risk and volatility, ASND or JANX?

Ascendis Pharma A/S has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.23, suggesting that its share price is 223% more volatile than the S&P 500.

Does the media prefer ASND or JANX?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Janux Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.64 beat Janux Therapeutics' score of 0.39 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings & valuation, ASND or JANX?

Janux Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Janux Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$288.08M	26.99	-$521.07M	-$8.08	-15.86
Janux Therapeutics	$8.08M	264.48	-$58.29M	-$1.17	-34.80

Do analysts rate ASND or JANX?

Ascendis Pharma A/S presently has a consensus target price of $192.07, indicating a potential upside of 49.90%. Janux Therapeutics has a consensus target price of $89.90, indicating a potential upside of 120.78%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Janux Therapeutics	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.08

Is ASND or JANX more profitable?

Ascendis Pharma A/S has a net margin of -130.33% compared to Janux Therapeutics' net margin of -463.91%. Ascendis Pharma A/S's return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-130.33%	N/A	-48.77%
Janux Therapeutics	-463.91%	-10.47%	-9.86%

Does the MarketBeat Community prefer ASND or JANX?

Ascendis Pharma A/S received 398 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 71.19% of users gave Janux Therapeutics an outperform vote while only 66.57% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%
Janux Therapeutics	Outperform Votes 42 71.19%	Underperform Votes 17 28.81%

Do institutionals & insiders hold more shares of ASND or JANX?

75.4% of Janux Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Janux Therapeutics beats Ascendis Pharma A/S on 10 of the 19 factors compared between the two stocks.